Abstract CT229: Olaparib in patients (pts) with previously treated, homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD)-positive advanced cancer: Phase II LYNK-002 study
Year: 2019
Type: conference-abstract
Source: Clinical Trials
Institutions: Memorial Sloan Kettering Cancer Center, Cedars-Sinai Medical Center, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Azienda Ospedaliera Universitaria Senese, Institut Gustave Roussy, Copenhagen University Hospital, AstraZeneca (United States), Merck & Co., Inc., Rahway, NJ, USA (United States), Sheba Medical Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4230815642